Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details Textual)

v3.7.0.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2016
Sep. 30, 2015
May 31, 2015
Mar. 31, 2015
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Stock Issued During Period, Value, Issued for Services         $ 0    
Proceeds from Issuance of Common Stock         0 $ 570,000  
Revenue from Related Parties         693,000 277,000  
Neupharma [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees       $ 1,000,000      
Revenue from Related Parties         260,000 200,000  
Neupharma [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         40,000,000    
Neupharma [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         40,000,000    
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         22,500,000    
Dana-Farber [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Shares Issued, Price Per Share     $ 0.065        
Stock Issued During Period, Shares, Issued for Services   136,830 500,000        
Stock Issued During Period, Value, Issued for Services   $ 600,000 $ 32,500        
Payment Of Upfront Fees       $ 1,000,000      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners     5.00%        
Proceeds from Issuance of Common Stock   $ 10,000,000          
Dana-Farber [Member] | Clinical Development, Regulatory and First Commercial Sale Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         21,500,000    
Maximum Potential Milestone Payments         21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         60,000,000    
Maximum Potential Milestone Payments         60,000,000    
Teva Pharmaceutical Industries Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees             $ 500,000
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         206,500,000    
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         220,000,000    
Jubilant Biosys Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees $ 2,000,000       400,000    
Revenue Recognition, Milestone Method, Revenue Recognized         500,000    
Research and Development Cost, Shared Percentage 50.00%            
Jubilant Biosys Ltd [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         87,200,000    
Maximum Potential Milestone Payments         88,500,000    
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         59,500,000    
Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         25,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         61,700,000    
Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due $ 89,000,000            
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
License Expense         89,000,000    
Jubilant Biosys Ltd [Member] | Successful Completion of Toxicology Studies [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition, Milestone Method, Revenue Recognized         200,000    
Collaboration Agreement With TGTX [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Licensing Fee         500,000    
Revenue from Related Parties         17,000 $ 28,000  
Collaboration Agreement With TGTX [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         7,000,000    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         $ 14,500,000